Citius Oncology Files 8-K Report
Ticker: CTOR · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1851484
Sentiment: neutral
Topics: corporate-filing, 8-K, company-update
TL;DR
Citius Oncology filed an 8-K on Jan 7, 2025, covering other events and financial exhibits.
AI Summary
On January 7, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly known as TenX Keane Acquisition until March 15, 2021, is incorporated in Delaware and headquartered in Cranford, NJ.
Why It Matters
This filing provides an update on Citius Oncology's corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- TenX Keane Acquisition (company) — Former company name
- January 7, 2025 (date) — Date of report
- March 15, 2021 (date) — Date of former company name change
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits" as of January 7, 2025.
What was Citius Oncology, Inc. previously known as?
Citius Oncology, Inc. was formerly known as TenX Keane Acquisition until March 15, 2021.
When was the report filed?
The report was filed on January 7, 2025.
Where is Citius Oncology, Inc. headquartered?
The company's principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
What is the company's Standard Industrial Classification code?
The company's Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Filing Stats: 425 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2025-01-07 09:10:42
Filing Documents
- ea0226984-8k_citius.htm (8-K) — 23KB
- ea022698401ex99-1_citius.htm (EX-99.1) — 43KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-001407.txt ( ) — 255KB
- ctor-20250107.xsd (EX-101.SCH) — 3KB
- ctor-20250107_lab.xml (EX-101.LAB) — 33KB
- ctor-20250107_pre.xml (EX-101.PRE) — 22KB
- ea0226984-8k_citius_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On January 7, 2025, Citius Oncology, Inc. issued a press release announcing significant progress in preparations for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated January 7, 2025. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS ONCOLOGY, INC. Date: January 7, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2